CAB39 and cancer: These compounds were tested against a panel of 5 kinases, AMPK alpha1, HER2, ERK2, JNK1 and the LKB1/MO25/STRADa complex, that are frequently dysregulated in cancer, making them critical targets for therapeutic development.